Alkem Laboratories Ltd
NSE:ALKEM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Alkem Laboratories Ltd
Total Equity
Alkem Laboratories Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Alkem Laboratories Ltd
NSE:ALKEM
|
Total Equity
₹133.5B
|
CAGR 3-Years
13%
|
CAGR 5-Years
14%
|
CAGR 10-Years
15%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Total Equity
₹360.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Total Equity
₹329.2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Total Equity
₹778.2B
|
CAGR 3-Years
14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
11%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Total Equity
₹196.3B
|
CAGR 3-Years
18%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Total Equity
₹84.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
Alkem Laboratories Ltd
Glance View
Alkem Laboratories Ltd., founded in 1973, has emerged as a significant player in India's pharmaceutical landscape, deftly combining innovation with a robust distribution network. Anchored in Mumbai, Alkem began as a modest venture but quickly evolved into a powerhouse, renowned for manufacturing a broad spectrum of branded generics, over-the-counter products, and active pharmaceutical ingredients (APIs). The company's success lies in its ability to cater to both domestic and international markets, primarily thriving on the ever-increasing demand for affordable healthcare solutions. Its formidable market presence in India is supported by a strong sales force and an extensive distribution network, ensuring its therapies reach even the most remote corners of the country. Internationally, Alkem has carved a niche for itself, with the United States being one of its major export markets. It strategically entered this competitive arena, building a portfolio of ANDAs (Abbreviated New Drug Applications) that allowed it to provide lower-cost alternatives to big pharma's patented drugs. This not only fueled its revenue growth but also fortified its standing as a go-to source for quality generics. Alkem's research and development efforts underpin its commitment to healthcare innovation, as it constantly seeks to expand its therapeutic repertoire. By consistently focusing on quality, affordability, and resourceful adaptation to global healthcare needs, Alkem Laboratories Ltd. has managed to script a growth story that is both impressive and sustainable.
See Also
What is Alkem Laboratories Ltd's Total Equity?
Total Equity
133.5B
INR
Based on the financial report for Dec 31, 2025, Alkem Laboratories Ltd's Total Equity amounts to 133.5B INR.
What is Alkem Laboratories Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
15%
Over the last year, the Total Equity growth was 16%. The average annual Total Equity growth rates for Alkem Laboratories Ltd have been 13% over the past three years , 14% over the past five years , and 15% over the past ten years .